Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

Rhea-AI Summary

Spero Therapeutics (NASDAQ:SPRO), a clinical-stage biopharmaceutical company specializing in rare diseases and multi-drug resistant bacterial infections treatments, has scheduled its second quarter 2025 financial results conference call and webcast for Tuesday, August 12, 2025, at 4:30 p.m. ET.

During the call, management will present Q2 2025 financial results and provide a business update. Investors can access the call via phone (1-844-825-9789 domestic, 1-412-317-5180 international) using conference ID 10200686, or through the live audio webcast available on Spero's investor relations website.

News Market Reaction – SPRO

+6.60%

16 alerts

+6.60% News Effect

+4.1% Peak in 1 hr 37 min

+$8M Valuation Impact

$129M Market Cap

0.5x Rel. Volume

On the day this news was published, SPRO gained 6.60%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.1% during that session. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $8M to the company's valuation, bringing the market cap to $129M at that time.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12^th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update.

To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10200686, or click on this link and request a return call with passcode 0605709. The audio webcast can be accessed live on this link and also on the “Investor Relations” page of the Spero Corporate Website at https://www.sperotherapeutics.com/. The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com

Spero Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@sperotherapeutics.com

Spero Media Inquiries:
media@sperotherapeutics.com

FAQ

When is Spero Therapeutics (SPRO) reporting Q2 2025 earnings?

Spero Therapeutics will report Q2 2025 earnings on Tuesday, August 12, 2025 at 4:30 p.m. ET via conference call and webcast.

How can investors access Spero Therapeutics Q2 2025 earnings call?

Investors can dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) with ID 10200686, or access the webcast through Spero's investor relations website.

What is Spero Therapeutics' (SPRO) main business focus?

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections.

How long will Spero Therapeutics' Q2 2025 earnings webcast be available?

The archived webcast will be available on Spero's website for 30 days following the call.